Sector consensus Thermo Fisher Scientific, Inc.
Equities
TMO
US8835561023
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 438.34 USD | -2.20% |
|
-5.73% | -24.35% |
| 05-15 | Thermo Fisher Likely to Benefit From End-Market Recovery, but Structural Risks Remain, RBC Says | MT |
| 05-13 | Nuvation Bio Collaborates With Thermo Fisher Scientific For Lung Cancer Treatment | DJ |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
| 612.52 | +39.74% | 25 | |||||||
| 577.01 | +37.02% | 30 | |||||||
| 247.83 | +53.06% | 23 | |||||||
| 85.19 | +61.71% | 32 | |||||||
| 97.15 | +19.38% | 27 | |||||||
| 49.58 | +48.43% | 20 | |||||||
| 399.81 | +21.44% | 21 | |||||||
| 160.69 | +43.86% | 16 | |||||||
| 270.6 | +34.04% | 15 | |||||||
| 241.02 | +50.29% | 20 | |||||||
| 79.95 | +31.58% | 19 | |||||||
| 28 | +28.21% | 20 | |||||||
| 143.63 | +0.77% | 19 | |||||||
| 1,762.31 | +2.46% | 13 | |||||||
| 113.64 | +20.94% | 14 | |||||||
| 49.15 | +14.63% | 13 | |||||||
| 11.6 | +41.81% | 2 | |||||||
| 31.92 | +42.97% | 8 | |||||||
| 67.1 | +28% | 6 | |||||||
| Average | 264.67 | +32.65% | 18 | ||||||
| Weighted average by Cap. | 348.49 | +39.46% | 24 |
- Stock Market
- Equities
- TMO Stock
- Sector Thermo Fisher Scientific, Inc.
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















